Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00690443 · ClinicalTrials.gov registry record · Phase 2
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
A Phase 2 study, sponsored by Aegerion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00690443 is a Phase 2 study that has completed, run by Aegerion Pharmaceuticals. The registered enrollment target is 44 participants.
The verdict
NCT00690443, a Phase 2 study, has completed, sponsored by Aegerion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
Evaluate the efficacy of combination therapy AEGR-733 plus atorvastatin 20 mg versus monotherapy on serum lipoproteins over 4 and 8 weeks of therapy. The primary efficacy parameter is percent change in LDL-C after 8 weeks of therapy.
Interventions
- DRUG Atorvastatin
- DRUG AEGR-733
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00690443
The ClinicalTrials.gov registry entry for NCT00690443 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aegerion Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atorvastatin is the first listed.
NCT00690443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00690443 about?
NCT00690443 is a clinical study titled "Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia". Evaluate the efficacy of combination therapy AEGR-733 plus atorvastatin 20 mg versus monotherapy on serum lipoproteins over 4 and 8 weeks of therapy. The primary efficacy parameter is percent change in LDL-C after 8 weeks of therapy.
What is the current status of trial NCT00690443?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2008-05. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00690443?
The interventions under investigation include: Atorvastatin (DRUG), AEGR-733 (DRUG).
Who is sponsoring clinical trial NCT00690443?
This trial is sponsored by Aegerion Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.